Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001213900-25-103252
Filing Date
2025-10-29
Accepted
2025-10-29 07:30:27
Documents
3
Period of Report
2025-10-29

Document Format Files

Seq Description Document Type Size
1 REPORT OF FOREIGN PRIVATE ISSUER ea0262679-6k_nlspharma.htm 6-K 10050
2 PRESS RELEASE TITLED: "NLS PHARMACEUTICS AND KADIMASTEM HIGHLIGHT CONTINUED BIRD ea026267901ex99-1_nlspharma.htm EX-99.1 13683
3 GRAPHIC ex99-1_001.jpg GRAPHIC 160701
  Complete submission text file 0001213900-25-103252.txt   246327
Mailing Address THE CIRCLE 6 8058 ZURICH Switzerland
Business Address THE CIRCLE 6 8058 ZURICH Switzerland 41-41-618-80-00
NLS Pharmaceutics Ltd. (Filer) CIK: 0001783036 (see all company filings)

EIN.: 000000000 | State of Incorp.: V8 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-39957 | Film No.: 251426852
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)